MicroRNA‑126: A new and promising player in lung cancer (Review)
- Authors:
- Qijun Chen
- Shuanghua Chen
- Juanjuan Zhao
- Ya Zhou
- Lin Xu
-
Affiliations: Department of Immunology, Special Key Laboratory of Gene Detection and Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China, Department of General Medicine, The Third Hospital Affiliated to Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China, Department of Medical Physics, Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China - Published online on: November 12, 2020 https://doi.org/10.3892/ol.2020.12296
- Article Number: 35
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Lam S, Chari R, Lockwood W, Lam W, MacAulay C, Sin D, Gazdar A, Khoury J, Yao RS and You M: Progress in lung cancer chemoprevention. Cancer Epidem Biomar. 4:46–52. 2006. | |
|
Wang P, Yang D, Zhang H, Wei X, Ma T, Cheng Z, Hong Q, Hu J, Zhou H, Song Y, et al: Early detection of lung cancer in serum by a panel of microRNA biomarkers. Clin Lung Cancer. 16:313–319.e1. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu X, Li H, Long L, Hui L, Chen H, Wang X, Shen H and Xu W: MiR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai). 44:519–526. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Latronico MV, Catalucci D and Condorelli G: Emerging role of microRNAs in cardiovascular biology. Circ Res. 101:1225–1236. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C: MicroRNomics: A newly emerging approach for disease biology. Physiol Genomics. 33:139–147. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y, Chao FF, Cai YP, Teng W and Qiu CG: MiR-126 inhibits the proliferation of myocardial fibroblasts by regulating EGFL7-mediated EGFR signal pathway. Int J Clin Exp Med. 10:6158–6166. 2017. | |
|
Liu F, Zhang H, Lu S, Wu Z, Zhou L, Cheng Z, Bai Y, Zhao J, Zhang Q and Mao H: Quantitative assessment of gene promoter methylation in non-small cell lung cancer using methylation-sensitive high-resolution melting. Oncol Lett. 15:7639–7648. 2018.PubMed/NCBI | |
|
Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC and Liang G: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun. 379:726–731. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Chen Z, Cheng N, Li X, Chen J, Wu D, Dong M and Wu X: MicroRNA-126 inhibit viability of colorectal cancer cell by repressing mTOR induced apoptosis and autophagy. Onco Targets Ther. 13:2459–2468. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Song L, Li D, Gu Y, Wen ZM, Jie J, Zhao D and Peng LP: MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer. 17:e65–e75. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Świtlik WZ, Karbownik MS, Suwalski M, Kozak J and Szemraj J: Serum miR-210-3p as a potential noninvasive biomarker of lung adenocarcinoma: A preliminary study. Genet Test Mol Biomarkers. 23:353–358. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Świtlik W, Karbownik MS, Suwalski M, Kozak J and Szemraj J: MiR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Cancer Biomark. 21:479–488. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng W, Zhou Y, Lu J, Xu H, Lei L, Chen C, Zhao J and Xu L: The prognostic value of miR-126 expression in non-small-cell lung cancer: A meta-analysis. Cancer Cell Int. 17:712017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JE, Eom JS, Kim WY, Jo EJ, Mok J, Lee K, Kim KU, Park HK, Lee MK and Kim MH: Diagnostic value of microRNAs derived from exosomes in bronchoalveolar lavage fluid of early-stage lung adenocarcinoma: A pilot study. Thorac Cancer. 9:911–915. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Gu YY, Ma FC, He RQ, Li ZY, Zhai GQ, Lin X, Hu XH, Pan LJ and Chen G: Expression levels and co-targets of miRNA-126-3p and miRNA-126-5p in lung adenocarcinoma tissues: An exploration with RT-qPCR, microarray and bioinformatic analyses. Oncol Rep. 41:939–953. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Wang J, Cheng J and Yu X: Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 15:8412–8416. 2018.PubMed/NCBI | |
|
Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, Liu G, Kong W, Gao R and Su J: Antitumor effects of Tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A/VEGFR-2/ERK signaling pathway. Mol Med Rep. 17:4327–4336. 2018.PubMed/NCBI | |
|
Chen M, Peng W, Hu S and Deng J: MiR-126/VCAM-1 regulation by naringin suppresses cell growth of human non-small cell lung cancer. Oncol Lett. 16:4754–4760. 2018.PubMed/NCBI | |
|
Song F, Xuan Z, Yang X, Ye X, Pan Z and Fang Q: Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses. J Cell Biochem. 121:2690–2703. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Zhang YS, Zhang S, Cheng ZM, Yu JL, Zhou S and Song J: MiR-126-3p suppresses the growth, migration and invasion of NSCLC via targeting CCR1. Eur Rev Med Pharmacol Sci. 23:679–689. 2019.PubMed/NCBI | |
|
Wang J, Ding M, Zhu H, Cao Y and Zhao W: Up-regulation of long noncoding RNA MINCR promotes non-small cell of lung cancer growth by negatively regulating miR-126/SLC7A5 axis. Biochem Biophys Res Commun. 508:780–784. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Crawford M, Brawner E, Batte K, Yu L, Hunter MG, Otterson GA, Nuovo G, Marsh CB and Nana-Sinkam SP: MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 373:607–612. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Saintigny P, Ren H, Zou XC and Mao L: MicroRNA (miRNA) species differentially expressed between immortalized normal bronchial epithelial cells and non-small cell lung. Cancer Res. 373:607–612. 2008. | |
|
Song L, Li XX, Liu XY, Wang Z, Yu Y, Shi M, Jiang B and He XP: EFEMP2 suppresses the invasion of lung cancer cells by inhibiting epithelial-mesenchymal transition (EMT) and down-regulating MMPs. Onco Targets Ther. 13:1375–1396. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Tong W, Liao M and Chen D: Inhibition of arachidonate lipoxygenase12 targets lung cancer through inhibiting EMT and suppressing RhoA and NF-κB activity. Biochem Biophys Res Commun. 524:803–809. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tao L, Shu-Ling W, Jing-Bo H, Ying Z, Rong H, Xiang-Qun L, Wen-Jie C and Lin-Fu Z: MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelial mesenchymal transition (EMT) through targeting c-Myc. Biomed Pharmacother. 125:1099622020. View Article : Google Scholar : PubMed/NCBI | |
|
Jia Z, Zhang Y, Xu Q, Guo W and Guo A: MiR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncol Lett. 15:7369–7375. 2018.PubMed/NCBI | |
|
Yang X, Chen BB, Zhang MH and Wang XR: MicroRNA-126 inhibits the proliferation of lung cancer cell line A549. Asian Pac J Trop Med. 8:239–242. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ren G and Kang Y: A one-two punch of miR-126/126* against metastasis. Nat Cell Biol. 15:231–233. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Lu B, Sun L, Yan X and Xu J: Identification of candidate genes or microRNAs associated with the lymph node metastasis of SCLC. Cancer Cell Int. 18:1612018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Chen J, Guo Y, Wang B and Chu H: Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget. 8:53854–53872. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li FJ, Huang J, Ji D, Meng Q, Wang C, Chen S, Wang X, Zhu Z, Jiang C, Shi Y, et al: Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer. Oncol Lett. 14:89–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lauridant G, Kotecki N, Pannier D and Dansin E: The role of angiogenesis inhibitors in the treatment of lung cancer. Oncologie. 18:409–418. 2016. View Article : Google Scholar | |
|
Tian RH, Wu X, Liu X, Yang JW, Ji HL and Yan YJ: The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials. J Cancer Res Ther. 12:571–575. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hong G, Kuek V, Shi J, Zhou L, Han X, He W, Tickner J, Qiu H, Wei Q and Xu J: EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis. J Cell Physiol. 233:8526–8537. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, et al: Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 123:3997–4009. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Usuba R, Pauty J, Soncin F and Matsunaga YT: EGFL7 regulates sprouting angiogenesis and endothelial integrity in a human blood vessel model. Biomaterials. 197:305–316. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Monaco F, Gaetani S, Alessandrini F, Tagliabracci A, Bracci M, Valentino M, Neuzil J, Amati M, Bovenzi M, Tomasetti M and Santarelli L: Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication. Cancer Lett. 463:27–36. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Bai Y, Zhang F, Wang Y, Guo Y and Guo L: MiR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 391:1483–1489. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shen X, Zhi Q, Wang Y, Li Z, Zhou J and Huang J: Hypoxia induces multidrug resistance via enhancement of epidermal growth Factor-like domain 7 expression in non-small lung cancer cells. Chemotherapy. 62:172–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, et al: MiR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. J Exp Clin Cancer Res. 38:2722019. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino S, Acierno C and Licito A: Experimental study on the prevention of liver cancer angiogenesis via miR-126. Promising results for targeted therapy. Eur Rev Med Pharmacol Sci. 22:853–855. 2018.PubMed/NCBI | |
|
Pishavar E and Behravan J: MiR-126 as a therapeutic agent for diabetes mellitus. Curr Pharm Des. 23:3309–3314. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou F, Jia X, Yang Y, Yang Q, Gao C, Hu S, Zhao Y, Fan Y and Yuan X: Nanofiber-mediated microRNA-126 delivery to vascular endothelial cells for blood vessel regeneration. Acta Biomater. 43:303–313. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dong G, Lin XH, Liu HH, Gao DM, Cui JF, Ren ZG and Chen RX: Intermittent hypoxia alleviates increased VEGF and Pro-angiogenic potential in liver cancer cells. Oncol Lett. 18:1831–1839. 2019.PubMed/NCBI | |
|
Gu C, Zou S, He C, Zhou J, Qu R, Wang Q, Qi J, Zhou M, Yan S and Ye Z: Long non-coding RNA CCAT1 promotes colorectal cancer cell migration, invasiveness and viability by upregulating VEGF via negative modulation of microRNA-218. Exp Ther Med. 19:2543–2550. 2020.PubMed/NCBI | |
|
Yoon NA, Jung SJ, Choi SH, Ryu JH, Mani M, Lee UH, Vo MT, Jeon DY, Chung SW, Ju Lee B, et al: DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF-A expression. FEBS J. 287:2070–2086. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Boudria A, Abou Faycal C, Jia T, Gout S, Keramidas M, Didier C, Lemaître N, Manet S, Coll JL, Toffart AC, et al: VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop. Oncogene. 38:1050–1066. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: MiR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Qu Y, Wu J, Deng JX, Zhang YP, Liang WY, Jiang ZL, Yu QH and Li J: MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway. Oncotarget. 7:74217–74226. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ye L, Peng Y, Mo J and Yao Y: MiR-126 enhances VEGF expression in induced pluripotent stem cell-derived retinal neural stem cells by targeting spred-1. Int J Clin Exp Pathol. 11:1023–1030. 2018.PubMed/NCBI | |
|
Yücel EI and Sahin M: Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b. Mol Biol Rep. 47:1649–1658. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Tufman A, Behr J, Kiefl R, Goldmann T and Huber RM: Role of the erythropoietin receptor in lung cancer cells: Erythropoietin exhibits angiogenic potential. J Cancer. 11:6090–6100. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shang AQ, Xie YN, Wang J, Sun L, Wei J, Lu WY, Lan JY, Wang WW, Wang L and Wang LL: Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: A case-control study. Neoplasma. 64:453–459. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Hu Z, Zhou Y, Zhao G, Lei Y, Li G, Chen S, Chen K, Shen Z, Chen X, et al: The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers. Oncotarget. 8:90197–90214. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Santarelli L, Gaetani S, Monaco F, Bracci M, Valentino M, Amati M, Rubini C, Sabbatini A, Pasquini E, Zanotta N, et al: Four-miRNA signature to identify asbestos-related lung malignancies. Cancer Epidemiol Biomarkers Prev. 28:119–126. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Q, Yu L, Lin X, Zheng Q, Zhang S, Chen D, Pan X and Huang Y: Combination of serum miRNAs with serum exosomal miRNAs in early diagnosis for non-small-cell lung cancer. Cancer Manag Res. 12:485–495. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, Liu X, Le H and Zhang Y: Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One. 11:e01530462016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Ding M, Duan X, Feng X, Wang P, Jiang Q, Cheng Z, Zhang W, Yu S, Yao W, et al: Diagnostic value of plasma microRNAs for lung cancer using support vector machine model. J Cancer. 10:5090–5098. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bagheri A, Khorshid HRK, Tavallaie M, Mowla SJ, Sherafatian M, Rashidi M, Zargari M, Boroujeni ME and Hosseini SM: A panel of noncoding RNAs in non-small-cell lung cancer. J Cell Biochem. Nov;28.2018.doi: 10.1002/jcb.28111 (Epub ahead of print). | |
|
Kim MH, Jo EJ, Eom JS, Mok JH, Ki KL, Kim U, Park HK and Lee MK: Diagnostic value of microRNAs derived exosomes from bronchoalveolar lavage fluid in early stage lung adenocarcinoma. Chest. 150:703A2016. View Article : Google Scholar | |
|
Ulivi P, Petracci E, Marisi G, Baglivo S, Chiari R, Billi M, Canale M, Pasini L, Racanicchi S, Vagheggini A, et al: Prognostic role of circulating miRNAs in early-stage non-small cell lung cancer. J Clin Med. 8:1312019. View Article : Google Scholar | |
|
Chen SW, Wang TB, Tian YH and Zheng YG: Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer. Int J Clin Exp Pathol. 8:14983–14988. 2015.PubMed/NCBI | |
|
Donnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes RM and Busund LT: Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: Coexpression with vascular endothelial growth factor-A predict poor survival. Cancer. 117:3193–3200. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Zhu S, Tao Z and Ye S: High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with Non-small cell lung cancer. Cancer Med. 7:21–31. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MK, Jung SB, Kim JS, Roh MS, Lee JH, Lee EH and Lee HW: Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch. 465:463–471. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jusufovic E, Rijavec M, Keser D, Korošec P, Sodja E, Iljazović E, Radojević Z and Košnik M: Let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One. 7:e455772012. View Article : Google Scholar : PubMed/NCBI | |
|
Lønvik K, Sørbye SW, Nilsen MN and Paulssen RH: Prognostic value of the MicroRNA regulators Dicer and Drosha in non-small-cell lung cancer: Co-expression of Drosha and miR-126 predicts poor survival. BMC Clin Pathol. 14:452014. View Article : Google Scholar : PubMed/NCBI | |
|
Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, Li W, Liu G, Gao R and Su J: Tubeimoside-1 inhibits the proliferation and metastasis by promoting miR-126-5p expression in non-small cell lung cancer cells. Oncol Lett. 16:3126–3134. 2018.PubMed/NCBI | |
|
Rai MK, Goyal R, Bhutani MK, Kaneria J, Mahendru K and Sharma N: Efficacy and safety profile of combined targeted therapy against Egfr and Vegf in patients with previously treated advanced non-small-cell lung cancer: A systematic review and meta-analysis. Value Health. 18:A4302015. View Article : Google Scholar | |
|
Yin W, Zhu J, Gonzalez-Rivas D, Okumura M, Rocco G, Pass H, Jiang G and Yang Y: Construction of a novel bispecific antibody to enhance antitumor activity against lung cancer. Adv Mater. 30:e18054372018. View Article : Google Scholar : PubMed/NCBI | |
|
Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Sheikh AM, Yano S, Mitaki S, Haque MA, Yamaguchi S and Nagai A: A Mesenchymal stem cell line (B10) increases angiogenesis in a rat MCAO model. Exp Neurol. 311:182–193. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kong Z, Hong Y, Zhu J, Cheng X and Liu Y: Endothelial progenitor cells improve functional recovery in focal cerebral ischemia of rat by promoting angiogenesis via VEGF. J Clin Neurosci. 55:116–121. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan W, Zhao F, Zhao S, Zhang L, Shi L and Pang T: Knockdown of long noncoding RNA MEG3 impairs VEGF-stimulated endothelial sprouting angiogenesis via modulating VEGFR2 expression in human umbilical vein endothelial cells. Gene. 649:32–39. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu CM: Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 59:455–467. 2018.PubMed/NCBI | |
|
Li L, Liu H, Xu C, Deng M, Song M, Yu X, Xu S and Zhao X: VEGF promotes endothelial progenitor cell differentiation and vascular repair through connexin 43. Stem Cell Res Ther. 8:2372017. View Article : Google Scholar : PubMed/NCBI | |
|
Long L, Zhang X, Bai J, Li Y, Wang X and Zhou Y: Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: From regulatory mechanisms to clinical implications. Cancer Manag Res. 11:4413–4424. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XC, Du LQ, Tian LL, Wu HL, Jiang XY, Zhang H, Li DG, Wang YY, Wu HY, She Y, et al: Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer. 72:92–99. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Chen S, Liu J, Guo X, Xiang X, Dong T, Ran P, Li Q, Zhu B, Zhang X, et al: Long non-coding RNA PVT1-5 promotes cell proliferation by regulating miR-126/SLC7A5 axis in lung cancer. Biochem Biophys Res Commun. 495:2350–2355. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fortunato O, Gasparini P, Boeri M and Sozzi G: Exo-miRNAs as a new tool for liquid biopsy in lung cancer. Cancers (Basel). 11:8882019. View Article : Google Scholar | |
|
Kibria G, Ramos EK, Wan Y, Gius DR and Liu H: Exosomes as a drug delivery system in cancer therapy: Potential and challenges. Mol Pharm. 15:3625–3633. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kobayashi M, Sawada K, Miyamoto M, Shimizu A, Yamamoto M, Kinose Y, Nakamura K, Kawano M, Kodama M, Hashimoto K and Kimura T: Exploring the potential of engineered exosomes as delivery systems for tumor-suppressor microRNA replacement therapy in ovarian cancer. Biochem Biophys Res Commun. 527:153–161. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nie H, Xie X, Zhang D, Zhou Y, Li B, Li F, Li F, Cheng Y, Mei H, Meng H and Jia L: Use of lung-specific exosomes for miRNA-126 delivery in non-small cell lung cancer. Nanoscale. 12:877–887. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Qi P, Li Y, Liu X, Jafari FA, Zhang X, Sun Q and Ma Z: Cryptotanshinone suppresses non-Small cell lung cancer via microRNA-146a-5p/EGFR Axis. Int J Biol Sci. 15:1072–1079. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhang Y, Zhang Y, Liu W and Wang J: Cryptotanshinone inhibits lung cancer invasion via microRNA-133a/matrix metalloproteinase 14 regulation. Oncol Lett. 18:2554–2559. 2019.PubMed/NCBI | |
|
Hu X, Zhang F, Liu XR, Wu YT and Ni YM: Efficacy and potential MicroRNA mechanism for computed tomography-guided percutaneous radiofrequency ablation of primary lung cancer and lung metastasis from liver cancer. Cell Physiol Biochem. 33:1261–1271. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Barshack I, Meiri E, Rosenwald S, Lebanony D, Bronfeld M, Aviel-Ronen S, Rosenblatt K, Polak-Charcon S, Leizerman I, Ezagouri M, et al: Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression. Int J Biochem Cell Bio. 42:1355–1362. 2010. View Article : Google Scholar | |
|
Tafsiri E, Darbouy M, Shadmehr MB, Zagryazhskaya A, Alizadeh J and Karimipoor M: Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features. Tumour Biol. 36:1603–1612. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Hu H, Jiao D, Yan J, Xu W, Tang X, Chen J and Wang J: MiR-126-3p and miR-451a correlate with clinicopathological features of lung adenocarcinoma: The underlying molecular mechanisms. Oncol Rep. 36:909–917. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kontarakis Z, Rossi A, Ramas S, Dellinger MT and Stainier DYR: Mir-126 is a conserved modulator of lymphatic development. Dev Biol. 437:120–130. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Agudo J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M and Brown BD: The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat Immunol. 15:54–62. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ferretti C and La Cava A: MiR-126, a new modulator of innate immunity. Cell Mol Immunol. 11:215–217. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Peng J, Yu Z, Xue L, Wang JB, Li J, Liu D, Yang Q and Lin Y: The effect of foxp3-overexpressing Treg cells on non-small cell lung cancer cells. Mol Med Rep. 17:5860–5868. 2018.PubMed/NCBI | |
|
Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J, Ren T and Xu L: MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med. 17:252–264. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chu F, Hu Y, Zhou Y, Guo M, Lu J, Zheng W, Xu H, Zhao J and Xu L: MicroRNA-126 deficiency enhanced the activation and function of CD4+T cells by elevating IRS-1 pathway. Clin Exp Immunol. 191:166–179. 2018. View Article : Google Scholar : PubMed/NCBI |
